blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2558116

EP2558116 - AGENT FOR LOCALLY TREATING CERVICAL DYSPLASIAS [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  06.12.2019
Database last updated on 21.03.2026
FormerThe patent has been granted
Status updated on  17.02.2017
FormerGrant of patent is intended
Status updated on  03.11.2016
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
General Vectors GmbH
Hortensienstraße 38
12203 Berlin / DE
[2018/41]
Former [2018/33]For all designated states
Cichon, Günter
Hortenseinstraße 38
12203 Berlin / DE
Former [2017/20]For all designated states
General Vectors GmbH
Hortensienstrasse 38
12203 Berlin / DE
Former [2013/08]For all designated states
Charité Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin / DE
Inventor(s)01 / CICHON, Günter
Hindenburgdamm 30
12200 Berlin / DE
 [2013/08]
Representative(s)Hertin und Partner Rechts- und Patentanwälte PartG mbB
Kurfürstendamm 63
10707 Berlin / DE
[N/P]
Former [2017/12]Hertin und Partner Rechts- und Patentanwälte PartG mbB
Kurfürstendamm 54/55
10707 Berlin / DE
Former [2013/08]Boeckh, Tobias
HERTIN Anwaltssozietät Kurfürstendamm 54/55
10707 Berlin / DE
Application number, filing date11727394.615.04.2011
[2017/12]
WO2011DE75075
Priority number, dateDE2010101647516.04.2010         Original published format: DE102010016475
[2013/08]
Filing languageDE
Procedural languageDE
PublicationType: A2 Application without search report
No.:WO2011127924
Date:20.10.2011
Language:DE
[2011/42]
Type: A2 Application without search report 
No.:EP2558116
Date:20.02.2013
Language:DE
The application published by WIPO in one of the EPO official languages on 20.10.2011 takes the place of the publication of the European patent application.
[2013/08]
Type: B1 Patent specification 
No.:EP2558116
Date:22.03.2017
Language:DE
[2017/12]
Type: B2 New European patent specification 
No.:EP2558116
Date:08.01.2020
Language:DE
[2020/02]
Search report(s)International search report - published on:EP29.12.2011
ClassificationIPC:A61K39/00, A61K39/12, A61K35/761
[2016/18]
CPC:
A61K39/0011 (EP,US); A61K39/12 (EP,US); A61P31/20 (EP);
A61P35/00 (EP); A61P37/04 (EP); A61K2039/5254 (EP,US);
A61K2039/5256 (EP,US); A61K2039/541 (EP,US); A61K2039/585 (EP,US);
A61K2039/892 (EP,US); C12N2710/10043 (EP,US); C12N2710/20022 (EP,US);
C12N2710/20034 (EP,US) (-)
Former IPC [2013/08]A61K39/00, A61K39/12
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/08]
TitleGerman:MITTEL ZUR LOKALEN BEHANDLUNG VON ZERVIXDYSPLASIEN[2013/08]
English:AGENT FOR LOCALLY TREATING CERVICAL DYSPLASIAS[2013/08]
French:AGENT DE TRAITEMENT LOCAL DE DYSPLASIES CERVICALES[2013/08]
Entry into regional phase18.10.2012National basic fee paid 
18.10.2012Designation fee(s) paid 
18.10.2012Examination fee paid 
Examination procedure18.10.2012Examination requested  [2013/08]
23.05.2013Amendment by applicant (claims and/or description)
27.01.2015Despatch of a communication from the examining division (Time limit: M04)
21.05.2015Reply to a communication from the examining division
16.09.2015Despatch of a communication from the examining division (Time limit: M04)
07.01.2016Reply to a communication from the examining division
25.05.2016Communication of intention to grant the patent
23.09.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.11.2016Communication of intention to grant the patent
13.02.2017Fee for grant paid
13.02.2017Fee for publishing/printing paid
13.02.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.01.2015
Opposition(s)Opponent(s)01  21.12.2017  03.01.2018  ADMISSIBLE
GlaxoSmithKline Biologicals S.A.
P.O. Box rue de l'Institut 89
1330 Rixensart / BE
Opponent's representative
Racine, Sophie Christiane Carol
GSK
Legal & Compliance - Global Patents
79 New Oxford Street
London WC1A 1DG / GB
 [N/P]
Former [2018/06]
Opponent(s)01  21.12.2017  03.01.2018  ADMISSIBLE
GlaxoSmithKline Biologicals S.A.
P.O. Box rue de l'Institut 89
1330 Rixensart / BE
Opponent's representative
Racine, Sophie Christiane Carol
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford Middlesex TW8 9GS / GB
16.01.2018Invitation to proprietor to file observations on the notice of opposition
16.05.2018Reply of patent proprietor to notice(s) of opposition
03.09.2018Cancellation of oral proceeding that was planned for 08.02.2019
08.02.2019Date of oral proceedings
22.03.2019Legal effect of interlocutory decision in opposition
22.03.2019Date of oral proceedings
06.05.2019Despatch of minutes of oral proceedings
07.05.2019Despatch of interlocutory decision in opposition
27.08.2019Despatch of communication that the patent will be maintained as amended
29.11.2019Fee for printing new specification paid
Fees paidRenewal fee
29.04.2013Renewal fee patent year 03
26.03.2014Renewal fee patent year 04
29.04.2015Renewal fee patent year 05
30.03.2016Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.04.2011
AL22.03.2017
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MK22.03.2017
MT22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
TR22.03.2017
AT15.04.2017
IE15.04.2017
LU15.04.2017
BE30.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
[2020/33]
Former [2020/15]HU15.04.2011
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MK22.03.2017
MT22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
TR22.03.2017
AT15.04.2017
IE15.04.2017
LU15.04.2017
BE30.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2019/51]HU15.04.2011
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MK22.03.2017
MT22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
AT15.04.2017
IE15.04.2017
LU15.04.2017
BE30.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2019/46]HU15.04.2011
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MT22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
AT15.04.2017
IE15.04.2017
LU15.04.2017
BE30.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2019/31]HU15.04.2011
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MT22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
AT15.04.2017
IE15.04.2017
LU15.04.2017
BE30.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/43]CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MT22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
AT15.04.2017
IE15.04.2017
LU15.04.2017
BE30.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/40]CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
AT15.04.2017
IE15.04.2017
LU15.04.2017
BE30.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/23]CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
IE15.04.2017
LU15.04.2017
BE30.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/14]CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
LU15.04.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/09]CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
SM22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/06]CZ22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
SM22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2017/51]CZ22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
SM22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2017/50]CZ22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
Former [2017/49]CZ22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
Former [2017/48]CZ22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
RS22.03.2017
SE22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
Former [2017/41]FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
RS22.03.2017
SE22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
Cited inInternational search[XDI] WO2009106362  (CICHON GUENTER et al.)
 [A] WO2008138648  (TRANSGENE SA et al.)
 [AD]   STEINWAERDER D S ET AL.: "HUMAN PAPILLOMA VIRUS E6 AND E7 PROTEINS SUPPORT DNA REPLICATION OFADENOVIRUSES DELETED FOR THE E1A AND E1B GENES", MOLECULAR THERAPY., vol. 4, no. 3, September 2001 (2001-09-01), pages 211 - 216, XP001061267

DOI:   http://dx.doi.org/10.1006/mthe.2001.0447
 [A]   RUDIN C M ET AL: "An attenuated adenovirus ONYX-015 as mouthwash therapy for premalignant oral dysplasia", JOURNAL OF CLINICAL ONCOLOGY, vol. 21, no. 24, 15 December 2003 (2003-12-15), AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, pages 4546 - 4552, XP002982638, ISSN: 0732-183X, DOI: 10.1200/JCO.2003.03.544

DOI:   http://dx.doi.org/10.1200/JCO.2003.03.544
by applicantWO2009106362
 US2006171949
 US2007098719
 DE102004039875
   HOFFMANN ET AL., J. IMMUNOTHER, vol. 33, 2010, pages 136 - 145
   YANG ET AL., PROC NATL ACAD SCI U S A., vol. 91, no. 10, 10 May 1994 (1994-05-10), pages 4407 - 1
   HOFFMANN ET AL., J IMMUNOTHER., vol. 33, no. 2, February 2010 (2010-02-01), pages 136 - 45
   STEINWAERDER ET AL., MOL THER., vol. 4, no. 3, September 2001 (2001-09-01), pages 211 - 6
   MCGRORY WJ ET AL., VIROLOGY, vol. 163, no. 2, 1988, pages 614 - 7
   HOFFMANN ET AL., J. LMMUNOTHER, vol. 33, 2010, pages 136 - 145
   OHLSCHLAGER P ET AL., VACCINE, vol. 24, no. 15, 2006, pages 2880 - 2893
   P.L. TRIOZZI ET AL., J /MMUNOTHER, vol. 28, 2005, pages 382 - 38826
   B. KLENCKE ET AL., CLIN CANCER RES, vol. 8, 2002, pages 1028 - 1037
   J. TARTAGLIA ET AL., VIROLOGY, vol. 188, 1992, pages 217 - 232
   SCHWIEGER ET AL., CARCINOGENESIS, vol. 22, no. 9, September 2001 (2001-09-01), pages 1385 - 9250
OppositionWO2009106362
 US7659071
 WO2007121893
 WO2008106646
 WO2004060408
 US6706728
 DE102010016475
 US7659071
 WO2007121893
 WO2008106646
 WO2004060408
 US6706728
   STEINWAERDER ET AL.: "Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes", MOLECULAR THERAPY, vol. 4, no. 3, 2001, pages 211 - 216, XP001061267

DOI:   http://dx.doi.org/10.1006/mthe.2001.0447
   HOFFMANN, CORINNA ET AL.: "Combining T- cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice", JOURNAL OF IMMUNOTHERAPY, vol. 33, no. 2, February 2010 (2010-02-01), pages 136 - 145, XP008143422

DOI:   http://dx.doi.org/10.1097/CJI.0b013e3181badc46
   DE SOUZA, APD. ET AL.: "Genital CD 8+T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus", VACCINE, vol. 25, no. 1, 2007, pages 109 - 116, XP005797690
   LANZA, SILVIA R. ET AL.: "Simian recombinant adenovirus delivered by the mucosal route modulates gammadelta T cells from murine genital tract", VACCINE, vol. 28, no. 29, May 2010 (2010-05-01), pages 4600 - 4608, XP027474774

DOI:   http://dx.doi.org/10.1016/j.vaccine.2010.04.080
   HEIDEMAN, DANIELLE AM ET AL.: "Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer", MOLECULAR THERAPY, vol. 12, no. 6, 2005, pages 1083 - 1090, XP005166230

DOI:   http://dx.doi.org/10.1016/j.ymthe.2005.06.443
   BALAGUE, CRISTINA ET AL.: "Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes", JOURNAL OF VIROLOGY, vol. 75, no. 16, 2001, pages 7602 - 7611, XP002215977

DOI:   http://dx.doi.org/10.1128/JVI.75.16.7602-7611.2001
   GAMBOTTO, ANDREA ET AL.: "Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12", CANCER GENE THERAPY, vol. 6, no. 1, 1999, pages 45 - 53, XP055292160

DOI:   http://dx.doi.org/10.1038/sj.cgt.7700013
   CROYLE, MARIA A. ET AL.: "Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice", PLOS ONE, vol. 3, no. 10, 2008, pages e3548, XP055381714

DOI:   http://dx.doi.org/10.1371/journal.pone.0003548
   RUDIN, CHARLES M. ET AL.: "An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia", JOURNAL OF CLINICAL ONCOLOGY, vol. 21, no. 24, 2003, pages 4546 - 4552, XP002982638

DOI:   http://dx.doi.org/10.1200/JCO.2003.03.544
   APPLEDORN, DANIEL M. ET AL.: "Sublingual administration of an adenovirus serotype 5 (Ad5)- based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell -mediated responses against HIV antigens despite preexisting Ad5 immunity", CLINICAL AND VACCINE IMMUNOLOGY, vol. 18, no. 1, January 2011 (2011-01-01), pages 150 - 160, XP055453515

DOI:   http://dx.doi.org/10.1128/CVI.00341-10
   BABIUK, L. A. ET AL.: "Adenoviruses as vectors for delivering vaccines to mucosal surfaces", JOURNAL OF BIOTECHNOLOGY, vol. 83, no. 1, 2000, pages 105 - 113, XP004212158

DOI:   http://dx.doi.org/10.1016/S0168-1656(00)00314-X
   DIAZ-ARRASTIA , CONCEPCION ET AL.: "Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%", CLINICAL CANCER RESEARCH, vol. 7, no. 10, 2001, pages 3031 - 3033, XP055453527
   MEYSKENS, FRANK L. ET AL.: "Prevention of cervical intraepithelial neoplasia and cervical cancer", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 62, no. 6, 1995, pages 1417S - 1419S, XP055453535
   "the cervix", CANADIAN CANCER SOCIETY, Retrieved from the Internet
   "NCI Dictionary of Cancer terms", NIH, pages 1
   DOORBAR J: "The papillomavirus life cycle", JOURNAL OF CLINICAL VIROLOGY, vol. 32S, 2005, pages S7 - S15, XP055543437

DOI:   http://dx.doi.org/10.1016/j.jcv.2004.12.006
   DOORBAR J ET AL.: "The Biology and Life-Cycle of Human Papillomaviruses", VACCINE, 2012, pages F55 - F70, XP055543439

DOI:   http://dx.doi.org/10.1016/j.vaccine.2012.06.083
   HOFFMANN, CORINNA ET AL.: "Combining T- cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice", JOURNAL OF IMMUNOTHERAPY, vol. 33, no. 2, February 2010 (2010-02-01), pages 136 - 145
   DE SOUZA, APD. ET AL.: "Genital CD 8+T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus", VACCINE, vol. 25, no. 1, 2007, pages 109 - 116
   LANZA, SILVIA R. ET AL.: "Simian recombinant adenovirus delivered by the mucosal route modulates gammadelta T cells from murine genital tract", VACCINE, vol. 28, no. 29, May 2010 (2010-05-01), pages 4600 - 4608
   HEIDEMAN, DANIELLE AM ET AL.: "Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer", MOLECULAR THERAPY, vol. 12, no. 6, 2005, pages 1083 - 1090
   BALAGU, CRISTINA ET AL.: "Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes", JOURNAL OF VIROLOGY, vol. 75, no. 16, 2001, pages 7602 - 7611
   GAMBOTTO, ANDREA ET AL.: "Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12", CANCER GENE THERAPY, vol. 6, no. 1, 1999, pages 45 - 53
   CROYLE, MARIA A. ET AL.: "Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice", PLOS ONE, vol. 3, no. 10, 2008, pages E3548
   RUDIN, CHARLES M. ET AL.: "An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia", JOURNAL OF CLINICAL ONCOLOGY, vol. 21, no. 24, 2003, pages 4546 - 4552
   APPLEDORN, DANIEL M. ET AL.: "Sublingual administration of an adenovirus serotype 5 (Ad5)- based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell -mediated responses against HIV antigens despite preexisting Ad5 immunity", CLINICAL AND VACCINE IMMUNOLOGY, vol. 18, no. 1, January 2011 (2011-01-01), pages 150 - 160
   BABIUK, L. A. ET AL.: "Adenoviruses as vectors for delivering vaccines to mucosal surfaces", JOURNAL OF BIOTECHNOLOGY, vol. 83, no. 1, 2000, pages 105 - 113
   DIAZ-ARRASTIA , CONCEPCION ET AL.: "Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%", CLINICAL CANCER RESEARCH, vol. 7, no. 10, 2001, pages 3031 - 3033
   MEYSKENS, FRANK L. ET AL.: "Prevention of cervical intraepithelial neoplasia and cervical cancer", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 62, no. 6, 1995, pages 1417S - 1419S
   "the cervix", CANADIAN CANCER SOCIETY, Retrieved from the Internet
   "NCI Dictionary of Cancer terms", NIH, pages 1
   DOORBAR J: "The papillomavirus life cycle", JOURNAL OF CLINICAL VIROLOGY, vol. 32S, 2005, pages S7 - S15
   DOORBAR J ET AL.: "The Biology and Life-Cycle of Human Papillomaviruses", VACCINE, 2012, pages F55 - F70
   Zervixzytology (Auf dem Laufenden, 2016), (https://twitter.com/eurocytology)
   SCHIFFMAN M.; WENTZENSEN N.: "Human Papillomavirus (HPV) infection and the multi-stage carcinogenesis of cervical cancer", CANCER EPIDEMIOL BIOMARKERS PREV., vol. 22, no. 4, 2013, pages 553 - 560
   CUBURU N. ET AL: "Adenovirus vector-based prime-boost vaccination via heterologous routes induses cervicovaginal CD8+ T cell responses against HPV16 oncoproteins", INTERNATIONAL JOURNAL OF CANCER, 2017, pages 1 - 13
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.